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Objective: To examine if chest pain increases the risk of depression and anxiety, or, on the 26 
other hand, depression and anxiety increase the risk of chest pain onset in patients with coronary 27 
heart disease (CHD). 28 
Design: Prospective clinical study. 29 
Setting: 16 general practices in the Greater London Primary Care Research Network. 30 
Participants: 803 participants with a confirmed diagnosis of CHD at baseline on the Quality 31 
and Outcomes Framework (QOF) CHD registers. 32 
Main outcome measures: Rose Angina Questionnaire, HADS depression and anxiety 33 
subscales and PHQ-9 were assessed at seven time points, each 6 months apart. Multi-Level 34 
Analysis (MLA) and Structural Equation Modelling (SEM) were applied. 35 
Results: Chest pain predicts both more severe anxiety and depression symptoms at all time 36 
points until 30 months after baseline. However, although anxiety predicted chest pain in the 37 
short term with a strong association, this association did not last after 18 months. Depression 38 
had only a small, negative association with chest pain.  39 
Conclusions: In persons with CHD, chest pain increases the risk of both anxiety and depression 40 
to a great extent. However, anxiety and depression have only limited effects on the risk for chest 41 
pain. This evidence suggests that anxiety and depression tend to be consequences rather than 42 
causes of cardiac chest pain. Intervention studies that support persons with CHD by providing 43 
this information should be devised and evaluated, thus deconstructing potentially catastrophic 44 
cognitions and strengthening emotional coping.  45 
 46 





Coronary heart disease (CHD) is the number one cause of death worldwide.[1] Clinically, it is 50 
mainly characterized by chest pain.[2] Chest pain in a patient with known CHD could signify 51 
new or unresolved issues with the coronaries. Biopsychosocial issues such as social isolation, 52 
adverse life events, chronic health conditions, coping mechanisms, distress, anxiety, or 53 
depression may also play a role, as either the consequence or the cause of the chest pain. Several 54 
studies have shown that especially comorbid depression and anxiety frequently co-occur with 55 
chest pain cross-sectionally.[3-6] It is also clear that this comorbidity has a substantial 56 
additional impact on quality of life,[7] even when depression or anxiety are in remission.[4,8]  57 
The relationship may be two-sided. Longitudinal epidemiological research shows overall 58 
associations between psychological problems and chest pain. In patients with CHD, chest pain 59 
increases the risk of occurrence of a new depression more than 3-fold.[9] Chest pain is also 60 
associated with patients exhibiting 3-year chronic symptomatology of distress, as compared to 61 
patients with low chest pain symptoms throughout the same period.[10] The finding that 62 
patients with a depressive disorder are also at increased risk of developing CHD supports a 63 
bidirectional association.[11-13] Furthermore, in a meta-analysis the association between 64 
anxiety and risk of CHD in healthy individuals was explored.[14] The results of this study show 65 
that anxiety was associated with incident CHD at follow up (ranging from 2 to 20.9 years).  66 
 67 
Rationale 68 
Given the possibly bidirectional association between chest pain and depression and anxiety in 69 
patients with CHD, so far it remains unknown which factor contributes mostly to onset of the 70 
other. The question remains whether chest pain contributes to the onset of depression and 71 
anxiety more, or, the other way around, that depression and anxiety contribute to the onset of 72 
chest pain in patients with CHD more. A precise understanding of which factor is the strongest 73 
predictor in this association would be highly relevant to support decisions in clinical practice 74 
as well as in designing public health policies.  75 
 76 
Objective 77 
The aim of this longitudinal study is to examine if chest pain increases the risk of depression 78 
and/or anxiety, or, on the other hand, if depression and anxiety increase the risk of the onset of 79 






Study design and Setting 84 
Details of the cohort study protocol have been reported elsewhere.[15] The sampling frame 85 
comprised people on the Quality and Outcomes Framework (QOF) CHD registers kept by 86 
participating general practices. The Greater London Primary Care Research Network recruited 87 
sixteen General Practices from the inner city and suburban south London. Recruitment and 88 
baseline assessments were completed during 2008-2009.  89 
 90 
Participants 91 
The cohort was described in more detail elsewhere.[16] The sampling focus of the main study, 92 
of which data was used for the present study, was on patients with CHD. General practitioners 93 
are remunerated for keeping CHD registers under the QOF. Practices participating in this 94 
Framework and based in South London were recruited by the London Primary Care Research 95 
Network (PCRN). Recruitment was based on an ‘opt-in’ procedure. All patients on the CHD 96 
registers in participating general practices were firstly invited by the practices themselves to 97 
participate in the study. Those agreeing to be contacted were put through to the research team, 98 
who gave them further information about the study and provided a consent form. Consenting 99 
patients were assessed at baseline and then every six months over a 3-year period. Written, 100 
informed consent was obtained for all participants before the initial assessment was conducted. 101 
Ethical approval was granted through the Bexley and Greenwich Research Ethics Committee 102 
(REC reference number: 07/H0809/38).  103 
 104 
Measures 105 
Specific to this analysis, the measures of interest were the following: 106 
 107 
Rose Angina Questionnaire 108 
A modified version of the Rose Questionnaire[17] was used at baseline and all follow-up 109 
assessments to assess the presence and symptoms of chest pain. The modification consisted 110 
specifying a time period for the occurrence of chest pain, instead of asking if it "ever" occurred. 111 
At baseline the time period evaluated was one year before baseline. At each follow-up visit, the 112 
occurrence of chest pain since the previous visit was assessed. Published in 1962 with the 113 
purpose of detecting angina pectoris in field studies,[17] the Rose Questionnaire has been 114 
widely used to determine the prevalence of angina and CHD in a large number of 115 
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epidemiological studies across the world. The short version of the questionnaire was developed 116 
as some aspects of the original were deemed possibly redundant. It was established that a quick, 117 
three question method could just as efficiently detect the crucial predictive component of 118 
mortality: exertional pain.[18] Similar to past studies using the full version to identify patients 119 
with ‘non-exertional pain’ and ‘exertional pain’,[19] the short version of the Rose 120 
Questionnaire allows for this classification with just three questions. For the purposes of the 121 
UPBEAT-UK cohort, the chest pain categorical variable comprised three groups: ‘no pain’, 122 
‘exertional pain’, and ‘non-exertional pain’.[16] These three categories were also used for the 123 
present study. Participants who did not report having chest pain were classified as having ‘no 124 
chest pain’. Participants who did report having chest pain, but not when hurrying, walking 125 
uphill, etc. were classified as having ‘nonexertional chest pain’. Participants who reported chest 126 
pain that occurred on exertion (i.e. when hurrying, walking uphill, etc.) were classified as 127 
having ‘exertional chest pain’. 128 
 129 
Hospital Anxiety and Depression Scale (HADS) 130 
Participants completed the 14-item HADS,[20] originally intended to identify symptoms 131 
regarding the emotional component of a psychical illness, by distinguishing them from those 132 
physical items that may be caused by the physical condition itself. The one-factor scale was 133 
then divided into two separate scales of seven items each. The HADS scores the severity of 134 
depressive and anxiety symptoms, both subscales ranging from 0 to 21. These subscales of the 135 
HADS are well-validated and provide a probable diagnosis of depression (HADS-D) or anxiety 136 
(HADS-A) for those scoring above the cut point of 8, established as the optimal cut-off for 137 
detecting mild depression and anxiety.[21] The cut-off score for severe levels of depression or 138 
anxiety is 12. Thus, scores of 8-11 represent a possible diagnosis of depression or anxiety, and 139 
scores of 12 and higher represent a probable diagnosis of depression or anxiety. The HADS has 140 
been extensively validated[22] and both subscales of the HADS have a good internal 141 
consistency (Cronbach’s alpha for HADS-D ranges from 0·67 to 0·90; Cronbach’s alpha for 142 
HADS-A ranges from 0·68-0·93).[21] The HADS has been widely used in people with medical 143 
illnesses, and its factor structure was confirmed.[23-25] 144 
 145 
Patient Health Questionnaire (PHQ-9) 146 
The PHQ-9 was used to assess the severity of depressive symptoms. The PHQ-9 is a brief, 147 
validated instrument, consisting of 9 items, that scores each of the DSM-IV criteria for Major 148 
Depressive Disorder.[26] Each item is scored from 0 (not at all) to 3 (nearly every day). The 149 
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total score thus varies from 0 to 27, with higher scores indicating higher levels of depressive 150 
symptoms. Scores of 0-5, 6-10, 11-15, and 16-20 represent mild, moderate, moderately severe, 151 
and severe depression, respectively, where a score of 10 is used as a clinical cut-off.[27] 152 
 153 
Confounders 154 
Age, gender, ethnicity, relationship status, employment status, and educational level. 155 
 156 
Time points 157 
All measures were reported at seven time points, each six months apart, from t0 (baseline) to t6 158 
(36 months). These were recoded to the number of months, for example, t24 = follow up at 24 159 
months after baseline. 160 
 161 
Data Analysis 162 
DEMOGRAPHIC AND BASELINE CHARACTERISTICS 163 
First, initial data analysis was performed on the whole data set, to explore demographic 164 
variables and baseline characteristics.  165 
 166 
Next, the analyses consisted of 3 steps. For step 1 (multilevel analysis), the questionnaires were 167 
used as a categorized variable. For steps 2 and 3 (structural equation modelling), the 168 
questionnaires were used as a continuous variable. 169 
 170 
Step 1: as a first step, multilevel analysis (MLA) was performed to assess the variability at the 171 
practice level, to assess interdependence of variables over trajectories of time, and to assess the 172 
usefulness of the variables for incorporation in the next phase in which structural equation 173 
modelling (SEM) was planned. Three-valued recoded variables (PHQ-9, HADS-A and HADS-174 
D) were only used in the MLA which were aimed at getting a first impression of the one-way 175 
relationships with the Rose Questionnaire. Practices, demographic variables, as well as the 176 
predictor and dependent variables (Rose Questionnaire, HADS-D, HADS-A and PHQ-9) were 177 
taken into account. The Rose Questionnaire was considered to be ordinal and the transformation 178 
suggested by Rasbash et al.[28] was applied to use it as a dependent variable in the multilevel 179 
models. For PHQ-9, HADS-A and HADS-D, we used the categorised scores. All three have 180 
three ordered categories, and the same transformation as for the Rose Questionnaire was used 181 
to be able to use them as dependent variables. The original categorised scores were used when 182 
these variables were used as independents in the models. We first used a model with 3-levels 183 
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(Time point, Patient and Practices). This analysis showed that although there was some 184 
variation between the general practices, this variation was not associated with the outcomes. 185 
Hence a 2-level MLA model could be run leaving the practice level out of the model and 186 
keeping only the time point and patient level. As age, ethnicity, and relationship had no 187 
significant association with the Rose Questionnaire, PHQ-9, HADS-D and HADS-A, and 188 
gender, employment, and education showed an association, the latter were included in all 189 
multilevel models. HADS-D varied insufficiently for the values of the Rose Questionnaire to 190 
study the correlation of the latter with all time points. Hence HADS-D was not included in 191 
subsequent models. Thus, we only used PHQ-9 to represent depression, and HADS-A to 192 
represent anxiety.  193 
 194 
Step 2: at step 2 structural equation modelling (SEM) was performed, for which the 195 
questionnaires were used as a continuous variable (in contrast to the use of the questionnaires 196 
as categorized variables in the MLA in step 1). For structural equation models, it is essential 197 
that respondents have data at all time points. We used the cross-validation approach described 198 
in Adèr & Mellenbergh[29] to be able to assess the stability of our models. We started by 199 
randomly dividing the data into two datasets, A and B. Next, a three-step procedure was 200 
followed:  201 
First, modelling was done on dataset A. Only full cases were used, that is, respondents from 202 
whom data was collected at all seven time points. This provided two models: (a) One in which 203 
the Rose Questionnaire is used to predict HADS-A and depression as measured with the PHQ-204 
9 at later time points and, (b) a model in which both PHQ-9 and HADS-A predict the Rose 205 
Questionnaire at later time points. Once these models were established, in a second step, they 206 
were verified using dataset B. This procedure was followed to be able to check the stability and 207 
validity of the resulting models.  208 
Step 3: as a third step, the estimates in the final SEMs were refined using data of respondents 209 
of which data were not collected at later time points. 210 
For this step, the following procedure was followed, for the models in which anxiety (HADS-211 
A) and depression (PHQ-9) were explored: 212 
1.  We started from the model fitted on the second half of the dataset of subjects who were 213 
present at all measurement points (baseline to 36 months). 214 
2.  We did a series of analyses, adding respondents that had all measurements up to month 30, 215 
month 24, month 18, month 12, month 6, and baseline (in that order). Note that the respondents 216 
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present in later analyses were always present in analyses with fewer time points (Thus, patients 217 
present in the 36-month analysis were present in all analyses). 218 
3.  Of each analysis, we used the estimates of arrows to and from the last time point to enhance 219 
the 36-months analysis. For the model exploring the association between chest pain and anxiety 220 
and depression, all time points were used. 221 
4.  As a fourth step, estimates for the time point corresponding to 36 months were left out as 222 
they were inconsistent between the analyses in the first modelling phase and the verification 223 
phase. The final models thus used the usual coding for PHQ-9 and HADS-A and have 30 224 
months as their last time point.  225 
As this is a longitudinal study, not a clinical trial, there are no events between time points that 226 
were planned in the design of the study. Therefore, it was sufficient to consider the predictive 227 
power of the Rose Questionnaire, HADS-A, and PHQ-9 at the first time point. Consequently, 228 
the term ‘lost-to-follow-up’ is not applicable here. In fact, in this study, data of cases with 229 
missing observations at later time points were used to improve the estimates after baseline as 230 
described above. 231 
 232 
RESULTS 233 
The sample is extensively described elsewhere.[9] Eight hundred three people participated 234 
(figure 3). Of this sample, 95.9% had a diagnosis of coronary artery disease (42.2% had a 235 
documented history of myocardial infarction and 53.7% a diagnosis of ischaemic heart disease 236 
or angina). The remaining 4.1% on the CHD register had a primary diagnosis of arrhythmia, 237 
heart failure, or not-specified. Of the total sample, 18.5% (149/803) met the criteria for an ICD-238 
10 defined diagnosis of a depressive or an anxiety disorder; 6.7% (54/803) met criteria for 239 
depressive disorder and 3.2% (26/803) for anxiety disorder. Demographic variables and 240 
baseline characteristics are given in Table 1. Most participant were male (69.9%), mean age 241 
was 71.1. The association between individual levels of the Rose questionnaire and the anxiety 242 
and depression measurements turns out to be comparable for all levels, including No Pain 243 
(results not shown).  244 
 245 
Table 1: Baseline characteristics of the total sample (N=803) 246 
Demographic variablesa   
Gender, n (%) Male 561 (69.9) 
 Female 242 (30.1) 
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Age, mean (SD)  71·1 (10.9) 
Education, n (%) < 2 years 376 (46.8) 
 > 2 years 415 (51.7) 
Employment, n (%) Unemployed 30 (3.7) 
 Paid work 148 (18.4) 
 Retired 619 (77.1) 
Outcome variablesa   
ROSE questionnaire, n (%) No chest pain 299 (37.2) 
 Exertional chest pain 94 (11.7) 
 Non-exertional chest pain 143 (17.8) 
PHQ-9, n (%) None or mild depressive symptoms 510 (63.5) 
 Moderate depressive symptoms 155 (19.3) 
 Severe depressive symptoms 136 (16.9) 
HADS anxiety score, n (%) <8 650 (80.9) 
 8-11 79 (9.8) 
 >11 71 (8.8) 
Abbreviations: SD = standard deviation; PHQ-9 = patient health questionnaire; HADS = hospital anxiety and 247 
depression scale 248 
aN differs due to missing data 249 
Numbers are based on the correction of variables in the preliminary analysis.  250 
 251 
Results of the SEM analysis are shown in Figures 1 and 2. As mentioned before, we used a 252 
cross-validation approach to assess the stability of the models. Figures 1 and 2 show the models 253 
found in the verification step of the SEM analysis. Only the structural model is shown. 254 
Coefficients in the Figures are standardized scores and in most cases coefficients < 0.1 have 255 
been left out. Figure 1 shows the prediction of anxiety and depressive symptoms by chest pain: 256 
chest pain predicts both more severe symptoms of anxiety and depressive at all time points. The 257 
associations in the model obtained in the verification step of the modelling process (using data 258 
set B) correspond to those obtained in the first step in which dataset A was used. The observed 259 




Figure 2 gives the prediction of chest pain by anxiety and depressive symptoms. Although more 262 
severe symptoms of anxiety were associated with chest pain in the first few timepoints (up to 263 
18 months), this association did not last. More severe symptoms of depression had a strong 264 
negative association with chest pain at baseline (-0.81) and at six months (-0.415), and only a 265 
small, negative association (-0.143) with chest pain after 24 months. Several links in the model 266 
obtained in the first step of the modelling process (using dataset A) had to be left out during the 267 
verification step (using data set B) since associations did not correspond. In particular, all links 268 
to the last time point (36 months) were left out.  269 






Our study shows that in patients with CHD, chest pain at baseline contributes to the onset of 274 
more severe symptoms of depression and anxiety more, with coefficients around 0.9, than the 275 
other way around. Depression and anxiety at baseline have only limited effects on the risk for 276 
onset of chest pain. Regarding the direction of the relationship between chest pain and 277 
depression or anxiety, our results suggests that more severe symptoms of depression and anxiety 278 
tend to be consequences of the pain rather than causes of it.  279 
Anxiety only has a short-term effect on chest pain, and depression seems to have a small 280 
protective effect against chest pain. One interpretation for this finding might be that medication 281 
could play a role in this. Beta blockers are frequently used in case of chest pain in CHD, in 282 
which fatigue is a common adverse effect; this might play a role in the level of physical activity, 283 
and hence the amount of experienced chest pain. Unfortunately, the level of physical activity 284 
was not available in this sample, so this possibility could not be explored. Also, research 285 
indicates that beta-blockers are associated with less depressive symptoms in patients with 286 
cardiac disorders.[30,31] This might explain the slight ‘protective’ effect on chest pain that was 287 
found in case of depression. Unfortunately, the use of medication in this sample was not 288 
available for analysis, so this possibility could not be further explored and this should be a topic 289 
for further research.  290 
 291 
Generalisability 292 
All the patients in this study were recruited from primary care CHD registers in the South 293 
London region. If patients were only at risk for CHD and not diagnosed as such, they were not 294 
in the register. Patients with no chest pain in this study still had CHD, probably somewhat under 295 
control due perhaps to a previous intervention, such as coronary artery bypass graft. Most 296 
patients were long-term CHD patients, who had had the usual treatments and medications. 297 
Hence, these study results apply to an urban population with CHD and more or less chest pain, 298 
which is primarily treated by their general practitioner. 299 
 300 
Limitations of the study 301 
The HADS-D subscale turned out to be unstable to such an extent in the preliminary MLA that 302 
it could not be used for analysis. This may be in line with the findings of a systematic review, 303 
which established that the ability of the HADS to differentiate between anxiety and depression 304 
is unclear.[32] The validity of the HADS to discern depression and anxiety from each other by 305 
its subscales has been subject to extensive debate in the literature[33] and our finding that the 306 
PHQ9 performed better is in line with such earlier findings. Fortunately, in our study the PHQ-307 
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9 was available for establishing levels of depression and the cross-validation enabled us to 308 
develop a stable structural model. The PHQ-9 includes items such as fatigue and sleeping too 309 
much, which might refer to the somatic component of depression but also to regular symptoms 310 
of CHD or as a side effect of medication. Hence we do not expect a particular bias in any 311 
direction. 312 
Another limitation is that this study is based on longitudinal cohort data that do not allow for 313 
controlling all theoretically possible factors that might play a role in causality, as it is not 314 
possible to randomize for such factors in a cohort study. No data were collected of 315 
pharmacotherapy or comorbid conditions, among others, which may have had an impact on the 316 
level of pain or psychological wellbeing of the patient. Moreover, in a qualitative study in a 317 
small sub-sample (n=30) of the UPBEAT study, patients reported a variety of themes which 318 
might impact the association between chest pain and depression and anxiety, such as social 319 
isolation, medical illness and disability, adverse life events, and coping mechanisms,[34] which 320 
might influence the association between chest pain and depression and anxiety. However, this 321 
is the first study that allows assuming a direction of causality, taking this limitation into account. 322 
The lack of data on physical activity is another limitation of this study. Anxiety and depression 323 
have its effect on physical exertion. For example, persons who are anxious about their 324 
cardiovascular symptoms, are more likely to avoid physical exertion. Furthermore, persons with 325 
a depression are more likely to be less active. In both cases, these persons are protected from 326 
exertional chest pain. Future research needs to take this into account. Furthermore, most 327 
participants in this study did not have a clinically diagnosed depressive or anxiety disorder at 328 
baseline. As a consequence, we were unable to test whether a possible relationship exists of 329 
chest pain with severity (measured with the HADS) of  diagnosed depression and anxiety. 330 
 331 
Clinical implications 332 
This is a finding of high clinical relevance. Patients with CHD fearing that worries might lead 333 
to increased symptomatology and thus worsening of the experience of their condition, can be 334 
assured that there is an insufficient ground for such fears. That may be a relief for patients 335 
fearing cardiac deterioration because of depressive or anxiety symptoms. Cardiologists and 336 
general practitioners can play an important role in assuring their patients. The core idea would 337 
be to help people deal with their chest pain symptoms and fatigue. To help them discern which 338 
chest pain would be a reason to visit the doctors for further investigation and how to tease these 339 
physical and psychological symptoms apart. Counselling patients and providing this 340 
information, deconstructing catastrophic cognitions, and strengthening emotional coping may 341 
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be an adequate approach given these findings. In a qualitative study in the UPBEAT sample, 342 
most participants found talking therapies and interventions providing the opportunity for social 343 
interaction, support and exercise, such as Cardiac Rehabilitation, to be helpful whereas anti-344 
depressants were not favoured.[34] Also, how to become or remain active and not give in to 345 
possibly paralysing feelings of demoralisation, and, last but not least, help patients alleviating 346 
possible feelings of guilt would be helpful. Such treatments could be delivered by trained 347 
general practice nurses or psychotherapists providing this in the context of Cognitive and 348 
Behavioural Therapy,[35] Acceptance and Commitment Therapy[36] or metacognitive 349 
therapy.[37] Hence, the findings of this study pertain to multiple professional audiences.  350 
Research implications 351 
Now that this study established that chest pain seems to primarily pose a risk for developing 352 
anxiety and depression and not the other way around, intervention studies should be devised 353 
and evaluated that support patients with CHD in coping with their chest pain at a psychological 354 
level. A qualitative study in the context of this study revealed that patients had issues with 355 
sexual problems, employment problems, and financial problems, besides their health 356 
problems.[38] Coming to terms not only with dealing with the chest pain in a de-catastrophizing 357 
way but also with these problems, may be required as the focus of new interventions. Further 358 
research is also needed to explore the role of other, biopsychosocial, factors (e.g. cardiac 359 
medication, physical activity, coping strategies, attachment style) in the interface of chest pain 360 
and anxiety and depression in CHD. 361 
 362 
Conclusion 363 
Psychological problems are the consequence rather than the cause of chest pain in primary care 364 
patients with stable CHD.  365 
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